Le Lézard
Classified in: Health, Science and technology, Covid-19 virus
Subject: PDT

New Healthcare AI eBook Offers Timely Insight and Education about Fraud, Waste and Abuse Threats


Payment integrity and FWA experts from Codoxo share the latest healthcare cost containment risks and best practices to inform leadership strategy for 2023 and beyond

ATLANTA , Jan. 31, 2023  /PRNewswire-PRWeb/ -- Codoxo, a trusted provider of healthcare artificial intelligence solutions for healthcare payers, agencies and pharmacy benefits managers (PBMs), today announced the release of its Forensic AI Alerts eBook: 2022 FWA Trends to Inform 2023 Cost Containment Strategies. The new eBook delivers healthcare leaders with the latest fraud, waste and abuse (FWA) threats that require real-time action, including emerging and evolving schemes, new treatments, the latest coding guidelines for viruses, and areas where upticks in fraudulent claims have been identified.

Codoxo's eBook is a culmination of Forensic AI Alerts curated throughout the year by Codoxo's team of payment integrity and FWA experts. These AI Alerts equip healthcare payers, agencies and PBMs with timely news and information about emerging trends, threats and schemes that may impact billing and their bottom lines.

"Healthcare leaders need trusted sources of information to help navigate trends and best practices that impact the rising cost of healthcare," said Rena Bielinski, Codoxo VP of Customer Success. "Our published reports highlight what's new and important, from common pitfalls in dental claims to updated telehealth billing codes. Our new eBook provides essential insights and recommendations that cost containment teams need to stay current and build impactful programs in the year ahead."

Highlights include:

 

In the healthcare industry, FWA is a multi-billion-dollar problem, accounting for as much as 10% of the $3.8 trillion spent on healthcare each year. It has commanded the attention of healthcare executives who want money-saving solutions. By providing specific steps for how to act quickly to protect healthcare dollars, Codoxo's eBook compliments its mission to help healthcare companies minimize risk and contain costs through artificial intelligence, machine learning and automation solutions.

To access Codoxo's eBook, visit https://www.codoxo.com/e-book-forensic-ai-alerts.

About Codoxo
With a mission to make healthcare more affordable and effective for everyone, Codoxo is the premier provider of artificial intelligence-driven solutions and services that help healthcare companies and agencies proactively detect and reduce risks from fraud, waste, and abuse and ensure payment integrity. The Codoxo Unified Cost Containment Platform helps clients manage costs across network management, clinical care, provider coding and billing, payment integrity, and special investigation units. Our software-as-a service applications are built on our proven Forensic AI Engine, which uses patented AI-based technology to identify problems and suspicious behavior far faster and earlier than traditional techniques. Our solutions are HIPAA-compliant and operate in a HITRUST-certified environment. For additional information, visit http://www.codoxo.com.

Media Contact

Ronda Duncan, Codoxo, 8472549782, [email protected]

 

SOURCE Codoxo


These press releases may also interest you

18 avr 2024
The 31st Canadian Cancer Society (CCS) Daffodil Ball, which took place this evening at Windsor Station in Montreal, raised $1,474,785 to fund innovative research projects and essential support programs for people living with cancer. The largest...

18 avr 2024
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

18 avr 2024
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....

18 avr 2024
The report titled "Progressive Familial Intrahepatic Cholestasis Treatment Market by Drug Type (Cholestyramine, Rifampicin, Ursodeoxycholic Acid), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End-Users - Global...

18 avr 2024
RevolKa Ltd. (Norio Hamamatsu, President & CEO), a venture-backed biotech company providing a game-changing protein engineering technology platform and La Jolla Institute for Immunology (LJI) (Erica Saphire, President & CEO) agreed to start a...

18 avr 2024
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...



News published on and distributed by: